Colchicine is a highly poisonous
natural product and
secondary metabolite, originally extracted from plants of the genus
Colchicum (
Autumn crocus,
Colchicum autumnale, also known as the "Meadow saffron"). Originally used to treat rheumatic complaints and especially
gout, it was also prescribed for its
cathartic and
emetic effects. Its present medicinal use is mainly in the treatment of gout; as well, it is being investigated for its potential use as an anti-
cancer drug. It can also be used as initial treatment for
pericarditis and preventing recurrences of the condition. In neurons,
axoplasmic transport is disrupted by colchicine.
History
Colchicum extract was first described as a treatment for gout in De Materia Medica by Pedanius Dioscorides in the first century CE.
The colchicine alkaloid was first isolated in 1820 by the two French chemists P.S. Pelletier and J. Caventon.
It was later identified as a tricyclic alkaloid, and its pain-relieving and anti-inflammatory effects for gout were linked to its ability to bind with tubulin.
Pharmacology
Biological function
Colchicine inhibits microtubule polymerization by binding to
tubulin, one of the main constituents of
microtubules. Availability of tubulin is essential to
mitosis, and therefore colchicine effectively functions as a "mitotic poison" or
spindle poison. Since one of the defining characteristics of cancer cells is a significantly increased rate of mitosis, this means that cancer cells are significantly more vulnerable to colchicine poisoning than are normal cells. However, the therapeutic value of colchicine against cancer is (as is typical with
chemotherapy agents) limited by its toxicity against normal cells.
Apart from inhibiting mitosis, a process heavily dependent on cytoskeletal changes, colchicine also inhibits neutrophil motility and activity, leading to a net anti-inflammatory effect. Colchicine also inhibits urate crystal deposition, which is enhanced by a low pH in the tissues, probably by inhibiting oxidation of glucose and subsequent lactic acid production in leukocytes. The inhibition of uric acid crystals is a vital aspect on the mechanism of gout treatment.
Colchicine as medicine
Colchicine is
Food and Drug Administration (FDA)-approved for the treatment of
gout and also for
familial Mediterranean fever, secondary
amyloidosis(AA), and
scleroderma. It is also used as an anti-inflammatory agent for long-term treatment of
Behçet's disease.
The Australian biotechnology company Giaconda has developed a combination therapy to treat constipation-predominant irritable bowel syndrome which combines colchicine with the anti-inflammatory drug olsalazine.
The British drug development company Angiogene is developing a prodrug of colchicine, ZD6126 (also known as ANG453) as a treatment for cancer.
Colchicine has a relatively low therapeutic index.
Colchicine is "used widely" off-label by naturopaths for a number of treatments, including the treatment of back pain.
Side effects
Side effects include gastro-intestinal upset and
neutropenia. High doses can also damage
bone marrow and lead to
anaemia. Note that all of these side effects can result from hyper-inhibition of mitosis.
Toxicity
Colchicine poisoning has been compared to
arsenic poisoning: symptoms start 2 to 5 hours after the toxic dose has been ingested and include burning in the mouth and throat,
fever,
vomiting,
diarrhea,
abdominal pain and
kidney failure. Death from respiratory failure can follow. There is no specific antidote for colchicine, although various treatments do exist.
Botanical use
Since
chromosome segregation is driven by microtubules, colchicine is also used for inducing
polyploidy in plant cells during
cellular division by inhibiting
chromosome segregation during
meiosis; half the resulting
gametes therefore contain no chromosomes, while the other half contain double the usual number of chromosomes (
i.e.,
diploid instead of
haploid as gametes usually are), and lead to embryos with double the usual number of chromosomes (
i.e. tetraploid instead of diploid). While this would be fatal in animal cells, in plant cells it is not only usually well tolerated, but in fact frequently results in plants which are larger, hardier, faster growing, and in general more desirable than the normally diploid parents; for this reason, this type of genetic manipulation is frequently used in breeding plants commercially. In addition, when such a tetraploid plant is crossed with a diploid plant, the
triploid offspring will be sterile, which may be commercially useful in itself by requiring growers to buy seed from the supplier, but also can often be induced to create a "seedless" fruit if pollinated (usually the triploid will also not produce pollen, therefore a diploid parent is needed to provide the pollen). This is the method used to create seedless
watermelons, for instance. On the other hand, colchicine's ability to induce polyploidy can be exploited to render infertile hybrids fertile, as is done when breeding
triticale from
wheat and
rye. Wheat is typically tetraploid and rye diploid, with the triploid hybrid infertile. Treatment with colchicine of triploid triticale gives fertile
hexaploid triticale.
When used to induce polyploidy in plants, colchicine is usually applied to the plant as a cream. It has to be applied to a growth point of the plant, such as an apical tip, shoot or sucker. Seeds can be presoaked in a colchicine solution before planting. As colchicine is so dangerous, it is worth noting that doubling of chromosome numbers can occur spontaneously in nature, and not infrequently. The best place to look is in regenerating tissue. One way to induce it is to chop off the tops of plants and carefully examine the lateral shoots and suckers to see if any look different.
References
External links
- Feature on colchicine, by Matthew J. Dowd at vcu.edu